An additional component of the study includes the development of magnetoencephalography (MEG) as a monitoring tool for PD. MEG provides a non-invasive method to study brain activity. Currently, there are not adequate assessment tools for monitoring disease progression or treatment protocols in PD. In preliminary experiments on PD patients and their caregivers, MEG data have indicated strong beta synchronization during rest in PD and milder beta desynchronization during movement preparation compared to age- and sex-matched controls. In this study, the amplitude of this pathological beta synchronization/desynchronization will be monitored to evaluate improvements in cortical brain function of PD patients treated with Leukine. MEG will be performed on PD patients and controls at the start of drug treatment, and on PD patients at the end of the drug treatment period and 4 weeks after drug is stopped.